Figure 2From: Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD (A) OS of combined cohort of 91 patients; (B) EFS of combined cohort of 91 patients. Back to article page